Rockefeller Capital Management’s Moleculin Biotech MBRX Stock Holding History

Rockefeller Capital Management’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.9K	Buy	15,000 +10,579	+239%	+$27K	﹤0.01%	3449
2026 Q1	$10.1K	Buy	4,421 +4,203	+1,928%	+$13.9K	﹤0.01%	3990
2025 Q4	$722	Sell	218 -362	-62%	-$3.37K	﹤0.01%	4492
2025 Q3	$7.69K	Buy	+580	New	+$7.83K	﹤0.01%	3743
2023 Q1	–	Sell	-5	Closed	-$1K	–	3108
2022 Q4	$1K	Hold	5	–	–	﹤0.01%	3711
2022 Q3	$1K	Hold	5	–	–	﹤0.01%	3746
2022 Q2	$2K	Sell	5 -2	-29%	-$1.16K	﹤0.01%	3804
2022 Q1	$4K	Hold	7	–	–	﹤0.01%	3424
2021 Q4	$5K	Hold	7	–	–	﹤0.01%	3278
2021 Q3	$8K	Sell	7 -1	-13%	-$1.17K	﹤0.01%	2998
2021 Q2	$10K	Hold	8	–	–	﹤0.01%	2778
2021 Q1	$12K	Buy	+8	New	+$14.7K	﹤0.01%	2514
2019 Q4	–	Sell	-1	Closed	-$3K	–	2144
2019 Q3	$3K	Buy	+1	New	+$2.58K	﹤0.01%	1731

Other funds holding MBRX

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EFG International Zurich $5.46B AUM

Rockefeller Capital Management's MBRX Position: Q2 2026 in Review

Rockefeller Capital Management increased its Moleculin Biotech (MBRX) stake by 239% in Q2 2026, buying an estimated $27K and bringing the position to 15,000 shares worth $41.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3449.

Rockefeller Capital Management first reported a position in MBRX in Q3 2019 and has held it in 13 quarters since. 18 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

Rockefeller Capital Management held 15,000 shares of Moleculin Biotech worth $41.9K as of Q2 2026.
Rockefeller Capital Management bought 10,579 Moleculin Biotech shares in Q2 2026, an estimated $27K.
Moleculin Biotech made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3449 holding.
Rockefeller Capital Management first reported a position in Moleculin Biotech in Q3 2019 and has held it in 13 quarters since.
18 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.